FindTrial
Sign In

Sitaxsentan

DRUG10 trials

Sponsors

West Penn Allegheny Health System, Pfizer, University of Edinburgh

Conditions

Blood PressureChronic Kidney DiseasePAH WHO Group IProteinuriaPulmonary Arterial HypertensionPulmonary HypertensionVasoconstrictionVasodilation

Early Phase 1

Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)
CompletedNCT01100736
University of EdinburghPulmonary Arterial Hypertension, Vasoconstriction, Vasodilation
Start: 2009-01-31End: 2010-01-31Target: 10Updated: 2015-07-21

Phase 1

A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
TerminatedNCT01244620
PfizerPulmonary Arterial Hypertension
Start: 2010-11-30End: 2010-12-31Updated: 2012-02-22
Drug Interaction Between Ritonavir And Sitaxsentan
WithdrawnNCT01251848
PfizerPulmonary Arterial Hypertension
Start: 2011-01-31End: 2011-02-28Updated: 2015-03-05
Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
WithdrawnNCT01251835
PfizerPulmonary Arterial Hypertension
Start: 2010-12-31End: 2011-01-31Updated: 2015-03-05

Phase 2

Sitaxsentan in Proteinuric Chronic Kidney Disease
CompletedNCT00817037
University of EdinburghBlood Pressure, Chronic Kidney Disease, Proteinuria
Start: 2007-07-14End: 2009-07-07Updated: 2025-02-07

Phase 3

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
TerminatedNCT00795639
PfizerPulmonary Arterial Hypertension, Pulmonary Hypertension
Start: 2008-12-31End: 2011-03-31Updated: 2015-03-24
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
TerminatedNCT00796510
PfizerPulmonary Arterial Hypertension, Pulmonary Hypertension
Start: 2010-07-31End: 2011-01-31Updated: 2018-10-25
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
TerminatedNCT00796666
PfizerPulmonary Arterial Hypertension, Pulmonary Hypertension
Start: 2009-05-31End: 2011-03-31Updated: 2015-03-24
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
TerminatedNCT00811018
PfizerPulmonary Arterial Hypertension
Start: 2003-03-31End: 2011-07-31Updated: 2012-04-24

Unknown Phase

Pharmacogenomics in Pulmonary Arterial Hypertension
WithdrawnNCT00593905
West Penn Allegheny Health SystemPAH WHO Group I, Pulmonary Arterial Hypertension, Pulmonary Hypertension
Start: 2005-07-31End: 2012-07-31Updated: 2021-12-09